Cell-free bioproduction and enzymatic manufacturing
Strategic Profile
Enzymit is developing cell-free bio-production technology eliminating inefficiencies, complexity and cost of current bio-production technologies, with small, modular bio-reactors that can efficiently convert available feedstocks into valuable products. The AI-powered platform designs entirely new enzymes tailored for specific production challenges, enabling creation of molecules and materials previously unattainable or prohibitively costly to produce.
Cyborg Score Rationale
Enzymit demonstrates solid technology differentiation with AI-powered enzyme design, significant Series A validation from tier-one investors (Khosla Ventures, Grove Ventures), and diverse commercial applications. Early-stage execution risks and capital intensity of bioproduction scale-up temper the outlook.
Top Insights
Enzymit closed a $10 million Series A funding round led by Grove Ventures and Khosla Ventures in September 2024, validating cell-free production technology and de-risking path to commercialization for applications spanning pharma, cosmetics, and food.
Enzymit demonstrated success in synthetically producing hyaluronic acid for cosmetic and therapeutic applications using computational protein design and deep learning, creating highly stable enzymes that withstand higher temperatures and work longer for efficient production.
Founded in 2020 by Dr. Gideon Lapidoth and COO Dror Baran, Enzymit operates with 11–50 employees and maintains active development pipeline targeting pilot-scale production facility post-funding, signaling transition from R&D to commercial deployment.
Named Competitors
DNA Script — Enzymatic DNA synthesis platform
Ansa Biotechnologies — Enzymatic nucleic acid synthesis platform for ultra-long DNA synthesis
Twist Bioscience — Enzymatic DNA synthesis and synthetic biology platform
Recent Developments
(September 2024) $10 million Series A funding round closed led by Grove Ventures and Khosla Ventures
(August 2023) Published peer-reviewed study on deep learning-based enzyme design efficacy
(August 2023) Demonstrated synthetic production of hyaluronic acid for cosmetics and therapeutics
Open the full interactive Enzymit Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.